Skip to main content
SpringerLink
Log in

Using yeast to study resistance to topoisomerase II-targeting drugs

  • Session 1: Topoisomerase Basic Science
  • Yeast, Topoisomerase, Resistance
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

We have developed a system utilizing the yeastSaccharomyces cerevisiae to probe the mechanism of action of anti-topoisomerase II drugs. This system has enabled us to dissect the mechanism of action of these agents. By inducing the overexpression of yeast topoisomerase II or by reducing the level of activity using temperaturesensitive mutations in topoisomerase II, we have demonstrated that conversion of topoisomerase II to a cellular poison plays a critical role in cell killing. We have also constructed other mutations in the yeastTOP2 gene that are resistant to etoposide and amsacrine and determined the DNA sequences for several of the drug-resistant alleles. The mutations that confer drug resistance map to several regions of theTOP2 gene. A mutation of particular interest changes Ser741 to Trp. This mutation results in hypersensitivity to etoposide but does not alter sensitivity to other agents such as mAMSA. We suggest that this mutation defines a site on theTOP2 protein that is involved in drug:protein interactions.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

mAMSA:

4-(9-acridinylamino)-methanesulfon-m-anisidide

CHO:

Chinese hamster ovary

MDR:

multi-drug resistance

References

  1. Beck WT, Danks MK (1991) Mechanisms of resistance to drugs that inhibit DNA topoisomerases. Semin Cancer Biol 2: 235

    Google Scholar 

  2. Beck WT, Cirtain MC, Danks MK, Felsted RL, Safa AR, Wolverton JS, Suttle DP, Trent JM (1987) Pharmacological, molecular, and cytogenetic analysis of “atypical” multidrug resistant human leukemia cells. Cancer Res 47: 5455

    Google Scholar 

  3. Bjornsti MA, Benedetti P, Viglianti- G, Wang JC (1989) Expression of human topoisomerase I in yeast cells lacking yeast DNA topoisomerase I: restoration of sensitivity of the cells to the antitumor drug camptothecin. Cancer Res 49: 6318

    Google Scholar 

  4. Bugg B, Danks MK, Beck WT, Suttle DP (1991) Expression of a mutant DNA topoisomerase II in CCRF-CEM human leukemia cells selected for resistance to teniposide. Proc Natl Acad Sci USA 88: 7654

    Google Scholar 

  5. DArpa P, Liu LF (1989) Topoisomerase-targeting anti-tumor drugs. Biochim Biophys Acta 989: 163

    Google Scholar 

  6. DiNardo S, Voelkel K, Sternglanz R (1984) DNA topoisomerase II mutant ofSaccharomyces cerevisiae topoisomerase II is required for the segregation of daughter molecules at the termination of DNA replication. Proc Natl Acad Sci USA 81: 2616

    Google Scholar 

  7. Drake FH, Zimmerman JP, McCabe FL, Bartus HF, Per SR, Sullivan DM, Ross WE, Mattern MR, Johnson RK, Crooke St, Mirabelli CK (1987) Purification of topoisomerase II from amsacrine-resistant P338 cells: evidence for two forms of the enzyme. J Biol Chem 262: 16739

    Google Scholar 

  8. Drlica K, Franco RJ (1988) Inhibitors of DNA topoisomerases. Biochemistry 27:2253

    Google Scholar 

  9. Elsea SH, Osheroff N, Nitiss JL (1992) Cytotoxicity of quinolones toward eukaryotic cells. J Biol Chem 267: 13150

    Google Scholar 

  10. Eng W-K, Faucette L, Johnson RK, Sternglanz R (1988) Evidence that DNA topoisomerase I is necessary for the cytotoxic effects of camptothecin. Mol Pharmacol 34: 755

    Google Scholar 

  11. Gaber RF, Couple DM, Kennedy BF, Vidal M, Bard M (1989) The yeast geneERG6 is required for normal membrane function but is not essential for biosynthesis of the cell-cycle-sparking sterol. Mol Cell Biol 9: 3447

    Google Scholar 

  12. Gootz TD, Barrett JF, Sutcliffe JA (1990) Inhibitory effects of quinolone anti-bacterial agents on eukaryotic topoisomerases and related test systems. Antimicrob Agents Chemother 34: 8

    Google Scholar 

  13. Goto T, Wang JC (1985) Cloning of yeastTOP1, the gene DNA encoding DNA topoisomerase I, and construction of mutants defective in both DNA topoisomerase I and topoisomerase II. Proc Natl Acad Sci USA 82: 7178

    Google Scholar 

  14. Graham TR, Scott PA, Emr SD (1993) Brefeldin A reversibly blocks early but not late protein transport steps in the yeast secretory pathway. EMBO J 12: 869

    Google Scholar 

  15. Hinds M, Deusseroth K, Mayes J, Altschuler E, Jansen R, Ledley FD, Zwelling LA (1991) Identification of a point mutation in the topoisomerase II gene from a human leukemia cell line containing an amsacrine-resistant form of topoisomerase II. Cancer Res 51: 4729

    Google Scholar 

  16. Holm C, Goto T, Wang JC, Botstein D (1985) DNA topoisomerase II is required at the time of mitosis in yeast. Cell 41: 553

    Google Scholar 

  17. Jannatipour M, Liu X-Y, Nitiss JL (1993) Thetop2-5 mutant of yeast topoisomerase II encodes an enzyme resistant to etoposide and mAMSA. J Biol Chem 268: 18586

    Google Scholar 

  18. Kato J, Nishimura Y, Imamura R, Niki H, Hiraga S, Suzuki H (1990) New topoisomerase essential for chromosome segregation inE. coli. Cell 63: 393

    Google Scholar 

  19. Kaufman S (1991) Antagonism between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukemia cell line. Cancer Res 51: 1129

    Google Scholar 

  20. Kreuzer K, Cozzarelli N (1979)Escherichia coli mutants thermosensitive for DNA gyrase subunit A: effects on DNA replication, transcription and bacteriophage growth. J Bacteriol 140: 425

    Google Scholar 

  21. Lee M-S, Wang JC, Beran M (1992) Two independent amsacrine-resistant human myeloid leukemia cell lines share an identical point mutation in the 170 kDa form of human topoisomerase II. J Mol Biol 223: 837

    Google Scholar 

  22. Liu LF (1989) DNA topoisomerase poisons as anti-tumor drugs. Annu Rev Biochem 58: 351

    Google Scholar 

  23. Nakamura S, Nakamura T, Kojima T, Yoshida H (1989)gyrA andgyrB mutations in quinolone-resistant strains ofEscherichia coli. Antimicrob Agents Chemother 33: 254

    Google Scholar 

  24. Nitiss J, Wang JC (1988) DNA topoisomerase-targeting anti-tumor drugs can be studied in yeast. Proc Natl Acad Sci USA 85: 7501

    Google Scholar 

  25. Nitiss J, Wang JC (1991) Yeast as a genetic system in the dissection of the mechanism of cell killing by topoisomerase-targeting anti-cancer drugs. In: Potmesil M, Kohn K (eds) DNA topoisomerases and cancer. Oxford University press, Oxford, p 77

    Google Scholar 

  26. Nitiss JL, Liu X-Y, Harbury P, Jannatipour M, Wasserman R, Wang JC (1992) Amsacrine and etoposide hypersensitivity of yeast cells overexpressing DNA topoisomerase II. Cancer Res 52: 4467

    Google Scholar 

  27. Nitiss JL, Liu X-Y, Hsiung Y (1993) A temperature sensitive topoisomerase II allele confers temperature dependent drug resistance to amsacrine and etoposide: a genetic system for determining the targets of topoisomerase II inhibitors. Cancer Res 53: 89

    Google Scholar 

  28. Nitiss JL, Liu X-Y, Jannatipour M (1993) Probing mechanisms of cell killing and resistance to anti-topoisomerase II agents using yeast. In: andoh T, et al. (eds) Molecular biology of DNA topoisomerases and its applications to chemotherapy. CRC, Boca Raton, p 287

    Google Scholar 

  29. Reece RJ, Maxwell A (1991) DNA gyrase: structure and function. CRC Crit Rev Biochem Mol Biol 26: 335

    Google Scholar 

  30. Robinson MJ, Osheroff N (1991) Effects of anti-neoplastic drugs on the post-strand passage DNA cleavage/religation equilibrium of topoisomerase II. Biochemistry 30: 1807

    Google Scholar 

  31. Robinson MJ, Martin BA, Gootz TD, McGuirk PR, Moynihan M, Sutcliffe JA, Osheroff N (1991) Effects of quinolone derivatives on eukaryotic topoisomerase II: a novel mechanism for enhancement of enzyme-mediated DNA cleavage. J Biol Chem 266: 14585

    Google Scholar 

  32. Thrash K, Bankier A, Barrell B, Sternglanz R (1985) Cloning, characterization, and sequencing of the yeast DNA topoisomerase I gene. Proc Natl Acad Sci USA 82: 4374

    Google Scholar 

  33. Tsai-Pflugfelder M, Liu AA, Tewey KM, Whang-Peng J, Knutsen T, Huebner K, Croce CM, Wang JC (1988) Cloning and sequencing of cDNA encoding human topoisomerase II and localization of the gene to chromosome region 17q21-22. Proc Natl Acad Sci USA 85: 7177

    Google Scholar 

  34. Wallis JW, Chrebet G, Brodsky G, Rolfe M, Rothstein R (1989) A hyper-recombination mutation inSaccharomyces cerevisiae identifies a novel eukaryotic topoisomerase. Cell 58: 409

    Google Scholar 

  35. Wasserman R, Austin CA, Fisher LM, Wang JC (1993) Use of yeast in the study of anti-cancer drugs targeting DNA topoisomerase: expression of a functional recombinant topoisomerase IIα in yeast. Cancer Res 53: 3591

    Google Scholar 

  36. Yamagishi J-I, Yoshida H, Yamayoshi M, Nakamura S (1986) Nalidixic acid resistant mutations of thegyrB gene ofEscherichia coli. Mol Gen Genet 204: 367–373

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Childrens Hospital, Los Angeles, MS 126, 4650 Sunset Boulevard, 90027, Los Angeles, CA, USA

    John L. Nitiss

  2. Departments of Pediatrics and Biochemistry, University of Southern California Medical School, Los Angeles, California, USA

    John L. Nitiss

Authors
  1. John L. Nitiss
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nitiss, J.L. Using yeast to study resistance to topoisomerase II-targeting drugs. Cancer Chemother. Pharmacol. 34 (Suppl 1), S6–S13 (1994). https://doi.org/10.1007/BF00684857

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00684857

Key words

Search

Navigation